Gastro hep advances最新文献

{"title":"Scarred From the Inside: A Case of Idiopathic Sclerosing Mesenteritis","authors":"Miguel E. Gomez , Michael L. Wells","doi":"10.1016/j.gastha.2025.100759","DOIUrl":"10.1016/j.gastha.2025.100759","url":null,"abstract":"","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"5 1","pages":"Article 100759"},"PeriodicalIF":0.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145230039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence–Assisted Endoscopy in Diagnosis of Gastrointestinal Tumors: A review of Systematic Reviews and Meta-Analyses","authors":"Olivier Sibomana ,&nbsp;Sulymon A. Saka ,&nbsp;Marie Grace Uwizeyimana ,&nbsp;Alex Mwangi Kihunyu ,&nbsp;Abraham Obianke ,&nbsp;Samuel Oluwo Damilare ,&nbsp;Lewis Tem Bueh ,&nbsp;Beloved of God Agbelemoge ,&nbsp;Richard Omoefe Oveh","doi":"10.1016/j.gastha.2025.100754","DOIUrl":"10.1016/j.gastha.2025.100754","url":null,"abstract":"<div><div>AI-assisted endoscopy has emerged as a promising tool for early and accurate detection of gastrointestinal (GI) tumors, which are associated with high morbidity, mortality, and financial burden. This review summarizes systematic reviews and meta-analyses on AI-assisted endoscopy in GI tumor diagnosis. A comprehensive search was conducted using PubMed/MEDLINE, Google Scholar, DOAJ, AJOL, and the Cochrane Library, supplemented by manual searches. Eligible systematic reviews and meta-analyses were selected based on predefined inclusion criteria, and relevant data were extracted to evaluate AI-assisted endoscopy’s diagnostic performance. Out of 569 identified studies, 23 systematic reviews with meta-analyses met the inclusion criteria, with 6 focusing on detection rates and 17 on diagnostic accuracy. AI-assisted endoscopy demonstrated a significantly higher detection rate for GI tumors compared to conventional endoscopy, alongside high diagnostic accuracy across different GI tumor types. However, variability in performance was observed among different AI algorithms and studies. While AI-assisted endoscopy enhances diagnostic precision, rigorous validation of AI models is necessary to ensure clinical reliability. Ethical considerations and further research are crucial for optimizing AI’s role in healthcare.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 9","pages":"Article 100754"},"PeriodicalIF":0.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145003853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PATIENT-REPORTED OUTCOME SCORES ARE COMPARABLE IN MULTIREGIONAL VERSUS UNIREGIONAL EOSINOPHILIC ESOPHAGITIS","authors":"Margaret H. Collins MD ,&nbsp;Zhaoxing Pan MB, PhD ,&nbsp;Guang-Yu Yang MD, PhD ,&nbsp;Nicoleta C. Arva MD, PhD ,&nbsp;Maria A. Pletneva MD ,&nbsp;Lisa J. Martin PhD ,&nbsp;Seema Aceves MD, PhD ,&nbsp;Mirna Chehade MD, MPH ,&nbsp;Evan S. Dellon MD, MPH ,&nbsp;Jonathan M. Spergel MD ,&nbsp;Paul Menard-Katcher MD ,&nbsp;Kathryn A. Peterson MD ,&nbsp;Paneez Khoury MD, MHSc ,&nbsp;Nirmala Gonsalves MD ,&nbsp;Sandeep K. Gupta MD ,&nbsp;Carla M. Davis MD ,&nbsp;Gary W. Falk MD ,&nbsp;Joshua B. Wechsler MD, MSci ,&nbsp;Robert Pesek MD ,&nbsp;Girish Hiremath MD, MPH ,&nbsp;Marc E. Rothenberg MD, PhD","doi":"10.1016/j.gastha.2025.100753","DOIUrl":"10.1016/j.gastha.2025.100753","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Eosinophilic esophagitis clinical trials often require multi-regional esophageal inflammation. To determine if patient-reported outcomes (PRO) worsen with multi-regional eosinophil inflammation (≥15 eosinophils/high power field (hpf)), we compared outcomes scores when multiple (proximal/mid/distal) esophageal regions, versus one, were inflamed.</div></div><div><h3>Methods</h3><div>The Consortium of Eosinophilic Gastrointestinal Researchers database was searched for peak eosinophil counts (PEC), EoE histology scoring system (EoEHSS) scores, and PRO scores (EoE Activity Index, EEsAI; Pediatric EoE Symptom Score, PEESSv2.0; EoE Quality of Life, QoL-A; Pediatric QL EoE modulev3.0, QL) in submissions from one or more regions. Analyses were performed with unadjusted or adjusted (adults: age, sex, dilation within 1 year; children: age, sex) data, using Wilcoxon rank sum and T test, and least squares mean, respectively. An interaction test was used for subgroup analysis. <em>P</em>≤.05 was considered significant.</div></div><div><h3>Results</h3><div>Adult PEC was 60.2±44.8 vs 39.5±29.9 (mean±SD, <em>P</em>&lt;.004), child PEC was 66.4±38.2 vs 38.2±31.5 (<em>P</em>=.0007) when two or more regions, vs one, were inflamed, respectively. Most symptoms and QoL scores did not differ when two or more regions (67 adults, 17 children) vs one (48 adults, 27 children) were inflamed: exceptions were modest worsening of one adult symptom domain (adjusted avoidance/modification/slow eating), and one child QL domain (chest pain/heartburn/stomach aches/nausea/vomiting/food regurgitation) (each <em>P</em>&lt;.043). EoEHSS scores were significantly increased with multi-regional inflammation in adults and children (all <em>P</em>&lt;.01), and scores correlated significantly with symptoms in one uni-regional group (0.29-0.38, <em>P</em>&lt;.01 to .05) but not any multi-regional group.</div></div><div><h3>Conclusions</h3><div>Multi-regional compared to uni-regional esophageal eosinophil inflammation does not significantly impact most PRO scores, and may not be necessary for all clinical trials.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 9","pages":"Article 100753"},"PeriodicalIF":0.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145003859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Swallowed Nasal Fluticasone Spray for Eosinophilic Esophagitis: An Affordable and Off-Label Path to Histologic Remission","authors":"Jameel Alp ,&nbsp;Alyssa M. Bren ,&nbsp;Tyson Sievers ,&nbsp;Joshua A. Sloan","doi":"10.1016/j.gastha.2025.100760","DOIUrl":"10.1016/j.gastha.2025.100760","url":null,"abstract":"<div><div>Swallowed topical corticosteroids are among the first-line therapies for eosinophilic esophagitis, with budesonide oral suspension recently approved by the Food and Drug Administration. However, off-label options such as fluticasone from metered-dose inhalers remain widely used due to cost and access barriers. We report a case of histologic remission achieved using over-the-counter fluticasone nasal spray administered orally with honey—an approach not previously described in the literature. This patient-led, low-cost method followed incomplete response to both proton pump inhibitors and fluticasone metered-dose inhaler. The case may illustrate a potential alternative steroid delivery method in eosinophilic esophagitis for resource-conscious, individualized care.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"5 1","pages":"Article 100760"},"PeriodicalIF":0.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145230038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aconitate decarboxylase 1 downregulates colitis and maintains homeostasis of the gut metabolome and microbiome","authors":"Kara M. McNamara ,&nbsp;Yvonne L. Latour ,&nbsp;Caroline V. Hawkins ,&nbsp;Kamery J. Williams ,&nbsp;Daniel P. Barry ,&nbsp;Margaret M. Allaman ,&nbsp;Alberto G. Delgado ,&nbsp;Sergei V. Chetyrkin ,&nbsp;M Wade Calcutt ,&nbsp;M. Blanca Piazuelo ,&nbsp;M. Kay Washington ,&nbsp;Shilin Zhao ,&nbsp;Lori A. Coburn ,&nbsp;Alain P. Gobert ,&nbsp;Keith T. Wilson","doi":"10.1016/j.gastha.2025.100748","DOIUrl":"10.1016/j.gastha.2025.100748","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Aconitate decarboxylase 1 (ACOD1) is implicated in innate immunity and inflammatory responses. We determined the role of ACOD1 in colon inflammation and colitis-associated carcinoma (CAC).</div></div><div><h3>Methods</h3><div>Human inflammatory bowel disease transcriptomic datasets and banked RNA samples were interrogated. C57BL/6 wild-type (WT) and <em>Acod1</em>^{<em>–/–</em>} mice were infected with <em>Citrobacter rodentium</em> or given one or two cycles of 4% dextran sulfate sodium (DSS) as models of colitis. For CAC, mice were given 12.5 mg/kg azoxymethane (AOM) followed by 3 cycles of 4% DSS. Clinical and histological parameters were assessed. Tissues and stool were used for metabolomic and 16S microbiome analyses, respectively.</div></div><div><h3>Results</h3><div><em>ACOD1</em> expression is increased in ulcerative colitis (UC) and Crohn’s disease (CD) tissues compared to controls. <em>C. rodentium</em> infection caused body weight loss only in <em>Acod1</em>^{<em>–/–</em>} mice, which had increased histologic injury versus wild-type. In DSS colitis, we observed decreased colon length and increased histologic injury in <em>Acod1</em>^{<em>–/–</em>} versus wild-type mice. AOM-DSS-treated <em>Acod1</em>^{<em>–/–</em>} animals exhibited more inflammation and injury but no difference in tumorigenesis. There was an altered metabolome in <em>Acod1</em>^{<em>–/–</em>} versus wild-type colon tissues, and during colitis, purine metabolism was most markedly affected. 16S microbiome analysis revealed significant differences in phyla and genera; notably an increase in <em>Bacteroidetes</em> and decrease in <em>Proteobacteria</em> in <em>Acod1</em>^{<em>–/–</em>} mice, indicating a dysbiotic state.</div></div><div><h3>Conclusions</h3><div>While ACOD1 is increased in human inflammatory bowel disease (IBD) tissues, our data indicate that this enzyme has a protective role in acute and chronic experimental colitis and is associated with prevention of intestinal dysbiosis and stabilization of the metabolome.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 9","pages":"Article 100748"},"PeriodicalIF":0.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145003858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extraintestinal symptoms of pain are common in patients with eosinophilic gastrointestinal diseases","authors":"Jennifer Dziwis MD MPH ,&nbsp;Xiangfeng Dai PhD ,&nbsp;Chelsea Anderson PhD MPH ,&nbsp;Ellyn Kodroff ,&nbsp;Mary Jo Strobel ,&nbsp;Amy Zicarelli ,&nbsp;Sarah Gray ,&nbsp;Amanda Cordell ,&nbsp;Girish Hiremath MD MPH ,&nbsp;Evan S. Dellon MD MPH ,&nbsp;Elizabeth T. Jensen MPH PhD","doi":"10.1016/j.gastha.2025.100732","DOIUrl":"10.1016/j.gastha.2025.100732","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Extraintestinal symptoms are well-documented in systemic, inflammation-predominant conditions. Less is understood about extra-gastrointestinal symptoms among individuals with eosinophilic esophagitis (EoE) and non-EoE eosinophilic gastrointestinal diseases (EGIDs). We aimed to describe the differences in the frequency of patient reported joint or leg pain, and headache for EoE and non-EoE EGIDs individuals.</div></div><div><h3>Methods</h3><div>Adult subjects and caregivers of children were recruited via the EGID Partners network and completed the Short Form-McGill Pain Questionnaire and Migraine Disability Assessment Test. T-tests were used to evaluate differences in extraintestinal pain symptomology by EGID type.</div></div><div><h3>Results</h3><div>We analyzed 95 subjects with EoE only and 24 subjects with non-EoE only EGIDs. Both EoE and non-EoE EGID subjects described frequent leg pain (50% and and 78%, respectively). While no significant difference was observed in number of days of leg pain, pain severity was higher for non-EoE EGID subjects (p&lt;0.01). Additionally, 78% of EoE only and 89% of non-EoE only EGID subjects reported joint pain, with no significant difference in the number of days of pain, but with higher pain severity for non-EoE EGID subjects (p&lt;0.01). Headache disability scores for non-EoE EGID subjects were more severe compared to subjects with EoE alone (17% of non-EoE EGIDs with severe disability vs 9% for EoE; p=0.01).</div></div><div><h3>Conclusions</h3><div>Patients with EGIDs may experience extraintestinal symptoms of pain. These symptoms may be more prominent in patients with non-EoE only EGIDs. Understanding of the underlying factors contributing to these symptoms is needed to guide mitigating approaches for these symptoms.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 10","pages":"Article 100732"},"PeriodicalIF":0.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Ehlers-Danlos Syndrome and Celiac Disease.","authors":"Nana Ama Adjei-Frimpong, Francesco Delacqua, Reid Oldenburg","doi":"10.1016/j.gastha.2025.100719","DOIUrl":"10.1016/j.gastha.2025.100719","url":null,"abstract":"","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 9","pages":"100719"},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disproportionate rates of liver injury in people with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor in Queensland, Australia","authors":"Ellie Johnson ,&nbsp;Timothy Riddles ,&nbsp;Daniel Smith ,&nbsp;Daniel Henderson ,&nbsp;Philip Masel ,&nbsp;David W. Reid ,&nbsp;Vanessa Moore ,&nbsp;Ieuan E.S. Evans","doi":"10.1016/j.gastha.2025.100641","DOIUrl":"10.1016/j.gastha.2025.100641","url":null,"abstract":"","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 6","pages":"Article 100641"},"PeriodicalIF":0.0,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neighborhood Socioeconomic Deprivation and 30-Day Outcomes After Admission for Common Gastrointestinal Conditions: A Large Nationwide Study","authors":"Beau Blass BS ,&nbsp;Jay B. Lusk MD, MBA ,&nbsp;Hannah Mahoney MS ,&nbsp;Molly N. Hoffman MPH ,&nbsp;Amy G. Clark PhD ,&nbsp;Jonathan Bae MD ,&nbsp;Matthew J. Townsend MD, MSc, MPP ,&nbsp;Amit Patel MD ,&nbsp;Andrew J. Muir MD, MHS ,&nbsp;Bradley G. Hammill DrPH","doi":"10.1016/j.gastha.2025.100614","DOIUrl":"10.1016/j.gastha.2025.100614","url":null,"abstract":"<div><h3>Background and Aims</h3><div>To study the associations of neighborhood socioeconomic disadvantage with 30-day mortality and readmission for common gastrointestinal conditions, adjusting for individual demographics, comorbidities, access to healthcare resources, and treatment facility characteristics.</div></div><div><h3>Methods</h3><div>We analyzed a nationwide sample of United States Medicare beneficiaries hospitalized from 2017-2019 for common gastrointestinal diseases, grouped by Diagnosis Related Groups (DRGs). We then estimated the association of neighborhood socioeconomic disadvantage, measured by the Area Deprivation Index (ADI), with 30-day mortality and readmission utilizing logistic regression models with restricted cubic splines. We performed multi-step adjustments for individual socioeconomic status and demographics, medical comorbidities, access to inpatient and outpatient healthcare resources, and hospital-level characteristics.</div></div><div><h3>Results</h3><div>In total, 1,293,483 patients in the mortality cohort and 1,289,106 patients in the readmission cohort were included in analysis. The fully-adjusted model demonstrated an association between neighborhood deprivation and 30-day mortality for patients with common gastrointestinal diseases, with the strongest associations for non-malignant pancreatic disorders (OR 1.59, 95% CI 1.25-2.01), esophageal disorders (OR 1.50, 95% 1.02-2.21), gastrointestinal hemorrhage (OR 1.40, 95% CI 1.29-1.52), and biliary tract disorders (OR 1.40, 95% CI 1.16-1.69) in the most deprived groups. Neighborhood deprivation was not associated with 30-day readmission after full adjustment.</div></div><div><h3>Conclusion</h3><div>We describe an independent association between neighborhood deprivation and 30-day mortality for patients with common gastrointestinal diseases, which remains even after controlling for individual poverty, demographics and comorbidities, access to healthcare resources, and characteristics of treating facilities.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 5","pages":"Article 100614"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143792377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Phenotypes May be Able to Identify Populations with Non-Alcoholic Fatty Liver-Spectrum Disease","authors":"Bridget M. Geyer MD, MSc ,&nbsp;Feier Chang ,&nbsp;Peng Wu ,&nbsp;Benjamin A. Goldstein PhD ,&nbsp;Kara Wegermann MD ,&nbsp;Sunny L. Chung MD ,&nbsp;Matthew Phelan MS ,&nbsp;Joseph Wawrzynski MD ,&nbsp;Jacqueline B. Henson MD ,&nbsp;Howard Lee MD ,&nbsp;Phil Ambery MBChB, FRCP, FFPM ,&nbsp;Cynthia A. Moylan MD, MHS ,&nbsp;Neha Pagidipati MD, MPH","doi":"10.1016/j.gastha.2024.100611","DOIUrl":"10.1016/j.gastha.2024.100611","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Despite causing significant morbidity and mortality, non-alcoholic fatty liver disease (NAFLD) is underdiagnosed. Clinical indices developed to identify hepatic steatosis are often used by providers but their potential for use at the population level remains unexplored. We assessed clinical phenotypes for their ability to identify potential patients with NAFLD and non-alcoholic steatohepatitis (NASH) in the electronic health record (EHR).</div></div><div><h3>Methods</h3><div>We conducted a single-center retrospective cohort study of adult patients from January 1, 2016-Decmber 31, 2022. We developed four phenotypes: clinical NAFLD (C-NAFLD), clinical NASH (C-NASH), NAFLD with diagnosis (D-NAFLD) and NASH with diagnosis (D-NASH) and compared characteristics across them to identify differences between patients with and without ICD diagnoses.</div></div><div><h3>Results</h3><div>Each of the (C) phenotypes identified a cohort of patients who had clinical evidence suggestive of disease without a documented diagnosis. Black patients were overrepresented in the (C) relative to (D) groups (C-NAFLD 24.3% vs. D-NAFLD 21.2%; C-NASH 28.5% vs. D-NASH 14.0%). Patients with D-NASH were more likely to be prescribed medications that may be effective in treating NAFLD-NASH spectrum disease, i.e., glucagon-like peptide 1 (GLP-1) receptor agonists (C-NASH 5.0% vs. D-NASH 16.7%, p &lt; 0.001). Fewer patients with D-NASH had cardiovascular (C-NASH 58.0% vs D-NASH 46.3%, p &lt; 0.001) and heart failure (C-NASH 33.9% vs. D-NASH 24.8%, p &lt; 0.001) hospitalizations than those with C-NASH.</div></div><div><h3>Conclusions</h3><div>Non-invasive clinical indices may improve identification of patients with or at risk for NAFLD-NASH at the population level. Systematic differences between populations with and without ICD diagnoses of NAFLD-spectrum disease suggest disparities in the application of screening and diagnostic procedures.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 5","pages":"Article 100611"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143792376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}